Skip to Main content Skip to Navigation
Journal articles

A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia

Abstract : We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab (eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with relapsed/refractory mantle cell lymphoma (MCL, n = 30) or Waldenström's macroglobulinemia (WM, n = 4), and in combination with rituximab in patients with marginal zone lymphoma (MZL, n = 21). All patients received atezolizumab monotherapy as maintenance for ≤10 cycles. Objective response rates at end of induction were 16.7% (MCL) and 42.9% (MZL), with no responses in WM. Median duration of response was 6.8 months (range 5.7-not estimable) for MCL and not reached for MZL. Treatment-emergent adverse events (TEAEs) occurred in 93.3%, 95.2% and 100% of MCL, MZL and WM patients, respectively. One fatal TEAE (pneumonia) occurred in each of the MCL and MZL groups. Biomarker analysis highlighted the importance of characterizing the immune environment to optimize efficacy of immunotherapy regimens.Trial registration details: EudraCT: 2016-003579-22.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03561708
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Tuesday, February 8, 2022 - 2:17:59 PM
Last modification on : Friday, August 5, 2022 - 11:55:11 AM
Long-term archiving on: : Monday, May 9, 2022 - 7:45:58 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Panayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, Vadim Ptushkin, Ana Marin-Niebla, et al.. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia. Leukemia & lymphoma, Taylor & Francis, 2022, pp.1-12. ⟨10.1080/10428194.2021.2015765⟩. ⟨inserm-03561708⟩

Share

Metrics

Record views

22